SG11201602331QA - Compositions and methods utilizing lysophosphatidylcholine scaffolds - Google Patents
Compositions and methods utilizing lysophosphatidylcholine scaffoldsInfo
- Publication number
- SG11201602331QA SG11201602331QA SG11201602331QA SG11201602331QA SG11201602331QA SG 11201602331Q A SG11201602331Q A SG 11201602331QA SG 11201602331Q A SG11201602331Q A SG 11201602331QA SG 11201602331Q A SG11201602331Q A SG 11201602331QA SG 11201602331Q A SG11201602331Q A SG 11201602331QA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods utilizing
- lysophosphatidylcholine
- scaffolds
- lysophosphatidylcholine scaffolds
- Prior art date
Links
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical group CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
- G01N2405/04—Phospholipids, i.e. phosphoglycerides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Environmental Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361882693P | 2013-09-26 | 2013-09-26 | |
US201461973136P | 2014-03-31 | 2014-03-31 | |
US201461992822P | 2014-05-13 | 2014-05-13 | |
PCT/US2014/057871 WO2015048554A1 (en) | 2013-09-26 | 2014-09-26 | Compositions and methods utilizing lysophosphatidylcholine scaffolds |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201602331QA true SG11201602331QA (en) | 2016-04-28 |
Family
ID=52744542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201602331QA SG11201602331QA (en) | 2013-09-26 | 2014-09-26 | Compositions and methods utilizing lysophosphatidylcholine scaffolds |
Country Status (9)
Country | Link |
---|---|
US (2) | US10175256B2 (en) |
EP (2) | EP3049429B1 (en) |
JP (3) | JP6692748B2 (en) |
CN (2) | CN105764917B (en) |
AU (3) | AU2014324651B2 (en) |
CA (1) | CA2925613A1 (en) |
ES (1) | ES2806751T3 (en) |
SG (1) | SG11201602331QA (en) |
WO (1) | WO2015048554A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3049429B1 (en) | 2013-09-26 | 2020-05-06 | National University of Singapore | Compositions and methods utilizing lysophosphatidylcholine scaffolds |
US10345302B2 (en) * | 2017-02-19 | 2019-07-09 | Sheng-He Huang | Circulating astrocytes and MFSD2A as biomarkers |
WO2018196011A1 (en) * | 2017-04-29 | 2018-11-01 | 韩婷 | Use of mfsd2a in preparing product for diagnosing purulent meningitis |
US10555957B2 (en) | 2017-05-10 | 2020-02-11 | The Board Of Trustees Of The University Of Illinois | Methods and compositions for enriching DHA levels in the brain |
JP2021508343A (en) | 2017-12-21 | 2021-03-04 | エーケル バイオマリーン アンタークティク エーエス | Lysophosphatidylcholine composition |
CN109932511B (en) * | 2019-03-22 | 2020-02-04 | 南昌大学第二附属医院 | Urine exosome phospholipid marker for liver cancer screening and kit thereof |
CN110361460A (en) * | 2019-06-18 | 2019-10-22 | 湖北省农业科学院畜牧兽医研究所 | A kind of discrimination method of laying duck stress situation |
BR112021025477A2 (en) * | 2019-06-20 | 2022-03-03 | Aker Biomarine Antarctic As | Parenteral lysophosphatidylcholine formulations like lpc-dha, lpc-epa and their uses in therapy |
JP2023521598A (en) | 2020-03-31 | 2023-05-25 | エーケル バイオマリーン アンタークティク エーエス | Krill oil composition enriched with LPC-DHA and LPC-EPA |
JPWO2022045020A1 (en) | 2020-08-25 | 2022-03-03 | ||
WO2022101678A2 (en) | 2020-11-15 | 2022-05-19 | Aker Biomarine Antarctic As | Lysophospholipid formulations |
WO2023166347A1 (en) * | 2022-03-04 | 2023-09-07 | Institut Pasteur | Uptake mechanism of essential lysophospholipids into the brain and inhibition by endogenous-retroviral envelope protein |
WO2023225249A1 (en) * | 2022-05-20 | 2023-11-23 | President And Fellows Of Harvard College | Methods and compositions relating to treatment of cns diseases |
KR20240011905A (en) * | 2022-07-19 | 2024-01-29 | 크로다코리아 주식회사 | Composition for preventing and improving memory loss comprising lysophospholipids derived from marine organism including Omega-3 fatty acid |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4425437A (en) | 1979-11-05 | 1984-01-10 | Genentech, Inc. | Microbial polypeptide expression vehicle |
US4431739A (en) | 1979-11-05 | 1984-02-14 | Genentech, Inc. | Transformant bacterial culture capable of expressing heterologous protein |
US4338397A (en) | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
US4452720A (en) | 1980-06-04 | 1984-06-05 | Teijin Limited | Fluorescent composition having the ability to change wavelengths of light, shaped article of said composition as a light wavelength converting element and device for converting optical energy to electrical energy using said element |
US4439356A (en) | 1981-03-03 | 1984-03-27 | Syva Company | Unsymmetrical fluorescein derivatives |
US4874795A (en) | 1985-04-02 | 1989-10-17 | Yesair David W | Composition for delivery of orally administered drugs and other substances |
US5330900A (en) | 1987-12-31 | 1994-07-19 | Tropix, Inc. | Chemiluminescent 3-(substituted adamant-2'-ylidene) 1,2-dioxetanes |
US5066580A (en) | 1988-08-31 | 1991-11-19 | Becton Dickinson And Company | Xanthene dyes that emit to the red of fluorescein |
US5227487A (en) | 1990-04-16 | 1993-07-13 | Molecular Probes, Inc. | Certain tricyclic and pentacyclic-hetero nitrogen rhodol dyes |
US5750409A (en) | 1991-11-18 | 1998-05-12 | Boehringer Mannheim Gmbh | Pentacyclic compounds and their use as absorption or fluorescent dyes |
US5716814A (en) * | 1996-02-02 | 1998-02-10 | Biomolecular Products, Inc. | Methods for making lysophosphatidylcholine |
US5847162A (en) | 1996-06-27 | 1998-12-08 | The Perkin Elmer Corporation | 4, 7-Dichlororhodamine dyes |
US6080852A (en) | 1996-06-27 | 2000-06-27 | The Perkin-Elmer Corporation | 4,7-dichlororhodamine dyes |
US6008379A (en) | 1997-10-01 | 1999-12-28 | The Perkin-Elmer Corporation | Aromatic-substituted xanthene dyes |
US5936087A (en) | 1997-11-25 | 1999-08-10 | The Perkin-Elmer Corporation | Dibenzorhodamine dyes |
US20020150626A1 (en) * | 2000-10-16 | 2002-10-17 | Kohane Daniel S. | Lipid-protein-sugar particles for delivery of nucleic acids |
ATE386986T1 (en) | 2001-07-06 | 2008-03-15 | Lipomics Technologies Inc | GENERATE, VIEW, INTERPRET AND USE A QUANTITATIVE DATABASE OF METABOLITES |
FR2836829B1 (en) * | 2002-03-11 | 2005-11-25 | Bio Merieux | USE OF L-ALPHA-LYSOPHOSPHATIDYLCHOLINE FOR DIFFERENTIATION OF MONOCYTES IN MATURE IN VITRO DENDRITIC CELLS |
PT1551370E (en) * | 2002-10-11 | 2008-02-07 | Idea Ag | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
US20060222699A1 (en) | 2005-03-29 | 2006-10-05 | Jonathan Gilinski | Flavored vegetarian cellulose capsule and methods for producing said capsule. |
US20090131368A1 (en) * | 2006-07-19 | 2009-05-21 | Su Chen | Mixtures of and methods of use for polyunsaturated fatty acid-containing phospholipids and alkyl ether phospholipids species |
US8262900B2 (en) | 2006-12-14 | 2012-09-11 | Life Technologies Corporation | Methods and apparatus for measuring analytes using large scale FET arrays |
CN102027019A (en) * | 2007-12-12 | 2011-04-20 | 大学健康网络 | High-density lipoprotein-like peptide-phospholipid scaffold (''HPPS'') nanoparticles |
CN101485887B (en) * | 2008-01-17 | 2011-06-29 | 中国人民解放军第二军医大学 | 5-fluorouracil-sn2-phosphatidyl choline copolymer as well as preparation method and application thereof |
CN102843922B (en) * | 2010-05-13 | 2015-12-16 | 尼特罗米加公司 | The neuroprotective of Xiao base Zhi Fang Suan – cognitive decline and/or suppression |
EP2646056A1 (en) * | 2010-12-02 | 2013-10-09 | Ben Gurion University of the Negev Research and Development Authority | Conjugates of a phospholipid and a drug for the treatment of inflammatory bowel disease |
KR101315483B1 (en) * | 2011-06-23 | 2013-10-07 | 주식회사 아리바이오 | A composition comprising antibiotics and lysophosphatidylcholine for enhancing immune or treating bacterial infection |
KR20140093347A (en) * | 2013-01-15 | 2014-07-28 | 삼성전자주식회사 | Genes inducing agonistic effects by anti-c-Met antibody treatment and drug method using thereof |
WO2014205338A2 (en) * | 2013-06-21 | 2014-12-24 | President And Fellows Of Harvard College | Methods and compositions relating to modulation of the permeability of the blood brain barrier |
US20160208329A1 (en) * | 2013-09-06 | 2016-07-21 | Cedars-Sinai Medical Center | Systems, devices and methods for anti-tl1a therapy |
EP3049429B1 (en) * | 2013-09-26 | 2020-05-06 | National University of Singapore | Compositions and methods utilizing lysophosphatidylcholine scaffolds |
-
2014
- 2014-09-26 EP EP14847279.8A patent/EP3049429B1/en active Active
- 2014-09-26 WO PCT/US2014/057871 patent/WO2015048554A1/en active Application Filing
- 2014-09-26 AU AU2014324651A patent/AU2014324651B2/en not_active Ceased
- 2014-09-26 CN CN201480064507.1A patent/CN105764917B/en active Active
- 2014-09-26 ES ES14847279T patent/ES2806751T3/en active Active
- 2014-09-26 US US15/025,181 patent/US10175256B2/en active Active
- 2014-09-26 CA CA2925613A patent/CA2925613A1/en not_active Abandoned
- 2014-09-26 SG SG11201602331QA patent/SG11201602331QA/en unknown
- 2014-09-26 JP JP2016545245A patent/JP6692748B2/en not_active Expired - Fee Related
- 2014-09-26 EP EP20173024.9A patent/EP3760638A3/en not_active Withdrawn
- 2014-09-26 CN CN202111106774.9A patent/CN113908296A/en active Pending
-
2018
- 2018-12-26 US US16/232,732 patent/US20190277866A1/en not_active Abandoned
-
2019
- 2019-02-13 AU AU2019201000A patent/AU2019201000A1/en not_active Abandoned
-
2020
- 2020-04-15 JP JP2020072904A patent/JP2020141676A/en not_active Withdrawn
-
2021
- 2021-11-16 AU AU2021269324A patent/AU2021269324A1/en not_active Abandoned
-
2022
- 2022-06-30 JP JP2022105833A patent/JP2022121623A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2015048554A1 (en) | 2015-04-02 |
EP3049429A1 (en) | 2016-08-03 |
AU2019201000A1 (en) | 2019-03-07 |
EP3760638A2 (en) | 2021-01-06 |
AU2021269324A1 (en) | 2021-12-09 |
US10175256B2 (en) | 2019-01-08 |
US20170067919A1 (en) | 2017-03-09 |
AU2014324651A1 (en) | 2016-04-14 |
CA2925613A1 (en) | 2015-04-02 |
EP3049429A4 (en) | 2017-08-02 |
CN105764917A (en) | 2016-07-13 |
JP2020141676A (en) | 2020-09-10 |
CN105764917B (en) | 2021-10-08 |
ES2806751T3 (en) | 2021-02-18 |
EP3760638A3 (en) | 2021-05-26 |
JP2022121623A (en) | 2022-08-19 |
US20190277866A1 (en) | 2019-09-12 |
AU2014324651B2 (en) | 2019-03-14 |
CN113908296A (en) | 2022-01-11 |
JP2016534747A (en) | 2016-11-10 |
JP6692748B2 (en) | 2020-05-13 |
EP3049429B1 (en) | 2020-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL273205A (en) | Compositions and methods | |
HK1218837A1 (en) | Compositions and methods | |
HK1218560A1 (en) | Compositions and methods | |
GB2520795B (en) | Compositions and methods | |
IL265876A (en) | Compositions comprising 15-ohepa and methods of using the same | |
SG11201602331QA (en) | Compositions and methods utilizing lysophosphatidylcholine scaffolds | |
HK1214171A1 (en) | Cenicriviroc compositions and methods of making and using the same | |
GB201308072D0 (en) | Compositions and methods | |
GB201304662D0 (en) | Compositions | |
GB201317636D0 (en) | Scaffold | |
IL276126B (en) | Compositions comprising l-4-chlorokynurenine and uses thereof | |
GB201305813D0 (en) | Compositions and methods | |
GB201310350D0 (en) | Curable compositions and membranes | |
GB201322456D0 (en) | Radiotracer compositions and methods | |
EP2964610A4 (en) | Vinylsulfone-based 18f-labeling compositions and methods and uses thereof | |
HK1226050B (en) | Purification method and compositions | |
PL3030719T3 (en) | Scaffold | |
GB201322617D0 (en) | Methods and compositions | |
GB201312393D0 (en) | Compositions and Methods | |
GB201308242D0 (en) | Compositions and uses thereof | |
GB201300628D0 (en) | Compositions comprising 15-OHEPA and methods of using the same | |
HU4298U (en) | Equipment for enhancing of cross-section in chimneys | |
GB201318736D0 (en) | Curable compositions and membranes | |
GB201304927D0 (en) | Compositions |